460738-38-9

Basic information

• Product Name: ecallantide
• Synonyms: ecallantide;DX 88
• CAS NO: 460738-38-9
• Molecular Formula: C305H442N88O91S8
• Molecular Weight: 7053.82798
• Mol File: 460738-38-9.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ecallantide(CAS DataBase Reference)
• NIST Chemistry Reference: ecallantide(460738-38-9)
• EPA Substance Registry System: ecallantide(460738-38-9)

Safety Data

• Hazardous Substances Data: 460738-38-9(Hazardous Substances Data)

Usage

Description

Ecallantide, also known as DX-88, is a 60-amino acid peptide with 3-disulfide bonds that functions as a potent and selective inhibitor of plasma kallikrein. It was designed using phage display technology and a library of designed variants of the first Kunitz domain of TFPI, differing from TFPI by 7-amino acids. Ecallantide was approved in 2009 in the United States for the treatment of hereditary angioedema (HAE), a condition characterized by episodic attacks of localized edema in cutaneous and mucosal tissues. It is a brand name drug called Kalbitor and has been developed as a subcutaneously administered formulation.

Uses

Used in Medical Applications:
Ecallantide is used as a treatment for hereditary angioedema (HAE) due to its ability to inhibit the action of plasma kallikrein, which is involved in the pathogenesis of HAE.
Used in Cardiothoracic Surgery:
Ecallantide is used as a plasma kallikrein inhibitor to reduce blood loss during cardiothoracic surgery, providing a more controlled and safer surgical environment.

Originator

Dyax Corp. (United States)

Related news

ecallantide (cas 460738-38-9) (DX-88) for acute hereditary angioedema attacks: Integrated analysis of 2 double-blind, phase 3 studies07/17/2019

BackgroundHereditary angioedema (HAE) is a rare disorder characterized by recurrent angioedema attacks. Ecallantide, a novel plasma kallikrein inhibitor, inhibits production of bradykinin, the key mediator of these angioedema attacks.detailed

Outcomes after ecallantide (cas 460738-38-9) treatment of laryngeal hereditary angioedema attacks07/16/2019

BackgroundHereditary angioedema (HAE) is a rare disorder associated with episodic attacks of well-demarcated angioedema. Attacks that affect the larynx can result in life-threatening airway obstruction.detailed

Response time for ecallantide (cas 460738-38-9) treatment of acute hereditary angioedema attacks07/15/2019

BackgroundHereditary angioedema (HAE) is a rare, debilitating, and potentially fatal disease characterized by acute attacks of swelling that can affect the abdomen/gastrointestinal tract, larynx, face, genitals, and extremities. Ecallantide is a novel plasma kallikrein inhibitor developed for th...detailed

Effectiveness of ecallantide (cas 460738-38-9) in treating angiotensin-converting enzyme inhibitor–induced angioedema in the emergency department07/14/2019

BackgroundAngiotensin-converting enzyme inhibitor–induced angioedema (ACEI-AE) is mediated by bradykinin. There remains an unmet treatment need because these patients, when presenting to the emergency department (ED), do not respond to conventional therapies, such as antihistamines and corticos...detailed

ecallantide (cas 460738-38-9) for the Acute Treatment of Angiotensin-Converting Enzyme Inhibitor–Induced Angioedema: A Multicenter, Randomized, Controlled Trial07/13/2019

Study objectiveWe compare the safety and efficacy of ecallantide with placebo in subjects undergoing assessment for acute angiotensin-converting enzyme inhibitor–induced angioedema (ACEIA) in an emergency department (ED).detailed

Characterization of Anaphylaxis After ecallantide (cas 460738-38-9) Treatment of Hereditary Angioedema Attacks07/11/2019

BackgroundEcallantide is a human plasma kallikrein inhibitor indicated for treatment of acute attacks of hereditary angioedema for patients 12 years of age and older. Ecallantide is produced in Pichia pastoris yeast cells by recombinant DNA technology. Use of ecallantide has been associated with...detailed